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Toll-like receptor engagement converts T-cell 
autoreactivity into overt autoimmune disease 
Karl S Lang1,7, Mike Recher1,7, Tobias Junt1, Alexander A Navarini1, Nicola L Harris1, Stefan Freigang1, 
Bernhard Odermatt1, Curdin Conrad2, Lars M Ittner3, Stefan Bauer4, Sanjiv A Luther5, Satoshi Uematsu6, 
Shizuo Akira6, Hans Hengartner1 & Rolf M Zinkernagel1
Autoimmune diabetes mellitus in humans is characterized by immunological destruction of pancreatic beta islet cells. We 
investigated the circumstances under which CD8+ T cells specific for pancreatic beta-islet antigens induce disease in mice 
expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) as a transgene under the control of the rat insulin 
promoter. In contrast to infection with LCMV, immunization with LCMV-GP derived peptide did not induce autoimmune diabetes 
despite large numbers of autoreactive cytotoxic T cells. Only subsequent treatment with Toll-like receptor ligands elicited overt 
autoimmune disease. This difference was critically regulated by the peripheral target organ itself, which upregulated class I 
major histocompatibility complex (MHC) in response to systemic Toll-like receptor–triggered interferon-α production. These 
data identify the 'inflammatory status' of the target organ as a separate and limiting factor determining the development of 
autoimmune disease.
Autoimmune diabetes in humans is characterized by  immunological 
destruction of beta islet cells in the pancreas and subsequent 
 hyperglycemia. T cells specific for beta islet cell antigens are likely to 
have a major role in the disease process1 and have been  suggested to 
arise  following exposure to viruses2–5 or infectious agents  containing 
cross-reactive epitopes (molecular mimicry)6. Indeed, Coxsackie virus 
and human cytomegalovirus contain proteins that share amino acid 
sequences with human GAD65, which is strongly expressed in the 
 pancreas7,8, and antigenic mimicry may explain the known  association 
of human leukocyte antigen (HLA)  haplotype and  disease development5. 
However, several viruses suspected to be  associated with diabetes do not 
contain any known cross- reactive e pitopes5, and approximately 50% 
of the European population is infected with human  cytomegalovirus9 
 without being diabetic, although human  cytomegalovirus has a cross-
reactive epitope with the beta islet antigen GAD65 (ref. 5). Autoreactive 
T cells have been detected in  individuals who do not show overt  disease10, 
suggesting that the onset of  autoimmune disease is not determined solely 
by the presence of  autoreactive T cells.
To find an explanation for these discrepancies, we examined RIP-GP 
mice, in which LCMV-GP is expressed as a transgene under the control 
of the rat insulin promoter (RIP)11–14. These mice have been previously 
used to show that diabetes can be induced by autoreactive cytotoxic 
T cells (CTL) that are primed by LCMV infection11 or by injection 
of peptide-pulsed mature dendritic cells (DCs)13. Disease could not 
be induced by infection with LCMV-GP-recombinant  vaccinia virus 
(VV-G2), despite the presence of activated autoreactive T cells14. These 
different outcomes may have resulted from variation in the magnitude 
of the T-cell response induced. Alternatively, LCMV, or mature DCs, 
may provide nonspecific inflammatory signals in  addition to  activating 
GP-specific T-cell responses, which could influence the efficiency of 
CD8+ T cell–mediated killing12, for instance by increasing expression 
of MHC I on the target organ14 or by enhancing migration of CD8+ 
T cells. Indeed, virus-induced production of chemokines is known to 
be important for T-cell migration into peripheral tissues and efficient 
antigen  clearance15, and chemokine production in pancreatic islets has 
been shown to have a role in T-cell infiltration into this organ16. Toll-
like receptor (TLR) signaling following recognition of distinct pathogen 
 patterns can also  influence the production of proinflammatory cyto-
kines and  chemokines by DCs and macrophages17–21. Eleven  different 
TLRs have been identified so far22, and these recognize molecular 
patterns such as RNA  (receptors TLR3, TLR7 and TLR8)23,24, DNA 
(TLR9)25 or l ipopolysaccharide (TLR4)26. The pattern of cytokine 
production following TLR ligation depends on the type of TLR, which 
results in a specifically optimized pathogen-host balance and may 
 occasionally result in autoimmune diseases27.
To analyze the role of such nonspecific immune stimuli in 
 autoimmunity, we analyzed the induction of diabetes in RIP-GP mice 
following  immunization with LCMV or with the immunodominant 
LCMV-GP–derived MHC class I peptide gp33 with or without  additional 
TLR ligation.
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RESULTS
Activated autoreactive T cells without disease
Mice expressing LCMV-GP as a transgene under the control 
of RIP were infected with 200 plaque-forming units (p.f.u.) of 
LCMV-WE  (intravenous). Consistent with previous observa-
tions11,14,  infection resulted in expansion of LCMV-GP33–41-spe-
cific CD8+ T cells  identified by tetramer binding (tet-gp33+ cells, 
Fig. 1a), and all infected mice developed hyperglycemia by day 
8–10 (Fig. 1a,e). Infection with the vaccinia virus expressing the 
LCMV-GP recombinant VV-G2 led to reduced expansion of tet-
gp33+ cells (Fig. 1b), and no diabetes occurred (Fig. 1b,e). To 
directly investigate the role of CTL frequency in the  induction 
of autoimmune disease, we immunized RIP-GP mice with the 
LCMV-GP-derived peptide gp33 together with CpG (ODN-1826) to 
deliver optimal costimulation. This immunization induced massive 
expansion of gp33-specific CD8+ T cells such that the frequency of 
these cells reached 40% of total CD8+ T cells (Fig. 1c). Nevertheless, 
all mice showed normal blood glucose concentrations, indicating the 
absence of disease (Fig. 1c,e). To further increase autoreactive T-cell 
frequencies, we adoptively transferred gp33-specific TCR-transgenic 
splenocytes (318 CD8+ T cells) into RIP-GP mice and immunized 
recipient mice with gp33 peptide alone. This protocol resulted in 
an expansion of the gp33-specific T cells up to a frequency of 80% 
of total CD8+ T cells (corresponding to 30% of total lymphocytes) 
even in the absence of costimulatory CpG (Fig. 1d). Still, only 20% 
of these mice developed hyperglycemia (Fig. 1d,e).
We reasoned that the absence of diabetes in RIP-GP mice showing 
high frequencies of gp33-specific CD8+ T cells could be explained 
by inadequate CTL effector function following peptide priming. 
We therefore examined the functional status of the gp33-specific 
318 CD8+ T cells following peptide immunization. Analysis of 
 surface marker expression showed a CD44high CD62Llow phenotype 
 suggestive of activation (Fig. 2a). These cells also expressed high  levels 
of the markers Ly6c+g and IL-2 receptor β-chain (CD122, Fig. 2a), 
 generally expressed by activated T cells. Peptide-stimulated TCR 
transgenic CD8+ T cells produced interferon-γ (IFN-γ) following 
in vitro  restimulation (Fig. 2b) and lysed peptide-pulsed target cells 
in ex vivo primary and secondary 51Cr release cytotoxicity assays 
(Fig. 2c). Furthermore, peptide-immunized mice were able to elimi-
nate gp33-labeled target splenocytes within 4 h in vivo, suggesting 
full lytic function in vivo of the gp33-specific 318 CTLs present in 
these mice (Fig. 2d).
Mice immunized with gp33 plus CpG (ODN-1826) without 
 previous transfer of transgenic 318 CD8+ T cells mounted a similar 
functional CTL response as shown by the ability of these mice to clear 
gp33-pulsed splenocytes in vivo within 4 h and an LCMV infection 
within 4 d (Fig. 2e,f).
Pancreatic T-cell infiltrations without disease
We next examined whether the functional beta islet cell–specific 
CTLs present in gp33 immunized mice did not induce  diabetes 
because of the lack of migration into the pancreas. To address 
this issue, we crossed the RIP-GP mice with mice expressing the 
 chemokine CXCL13/BLC under control of the rat insulin promoter 
(RIP-BLC), which have been previously described to display lymphoid 
 infiltrations within the endocrine pancreas28. Mice doubly transgenic for 
RIP-GP and RIP-BLC were transfused with transgenic gp33-specific 
 splenocytes (318), and recipient mice were immunized with gp33. 
This resulted in a rapid expansion of gp33-specific CD8+ T cells, 
such that their frequency approached 50% of total lymphocytes in 
blood (Fig. 3a). Infiltration of these peptide-activated CTLs into the 
pancreatic islets was shown by immunohistochemical analysis of the 
Vα2 TCR expressed by 318 CD8+ T cells (Fig. 3c), yet none of the 
mice  developed diabetes (Fig. 3a). This indicated that the presence 
of functional CTLs within the pancreas was not sufficient to induce 
diabetes. In contrast, infection of these mice with LCMV resulted 
in hyperglycemia (Fig. 3b), suggesting that some factor (other than 
CTL activation and migration into the pancreas) associated with viral 
infection had mediated induction of disease.
MHC class I upregulation by LCMV versus pepitide
We reasoned that the ability of LCMV infection to induce diabetes could 
be explained by virus-induced cytokine production rendering pancreatic 
beta islet cells susceptible to CTL-mediated destruction. Four days after 
LCMV infection, we detected strongly elevated serum IFN-α (Fig. 4a), 
a cytokine known to induce the upregulation of MHC class I29. Indeed, 
immunohistochemical analysis of beta islet cells infected with LCMV 
showed enhanced expression of MHC class I in LCMV-infected mice 
Figure 1  Expansion of CD8+ T cells specific for beta islet cell antigen 
alone does not necessarily induce diabetes. Filled square and filled circle, 
blood glucose concentrations. Open square, open circle, frequency of 
LCMV-GP33–41 (gp33) specific CD8+ T cells (tet-gp33+). (a) RIP-GP mice 
infected with 200 p.f.u. LCMV-WE intravenously (n = 3) (b) RIP-GP mice 
infected with 2 × 106 p.f.u. vaccinia virus recombinant for LCMV-GP 
intraperitoneally (VV-G2, n = 3) (c) RIP-GP mice immunized with gp33 
(1 mg in PBS) with CpG (ODN-1826, 50 µg in phosphate-buffered saline) 
on days 0, 2 and 5. On day 9, mice were challenged with peptide alone 
(n = 3). (d) RIP-GP mice injected intravenously with 107 splenocytes from 
LCMV-gp33/H-2Db-specific 318 TCR-transgenic mice and immunized with 
gp33 (1 mg in PBS) on days 0, 4 and 9 (n = 5). Filled square and open 
square, mice with normal blood glucose levels. Filled circle and open circle, 
mice developing diabetes. Eighty percent of mice showed normal blood 
glucose levels, and 20% developed diabetes. (e) Percentage of mice with 
diabetes at any time point following treatment protocols outlined in a–d. 
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(Fig. 4b), consistent with previous reports12,14. In contrast,  immunization 
with gp33 enhanced neither systemic IFN-α production nor MHC class I 
expression in pancreatic beta islet cells (Fig. 4a,b). Rag1–/–  mice  (lacking 
T and B cells) showed a smaller enhancement of MHC I expression 
after LCMV infection when  compared with naive and LCMV-infected 
C57BL/6 mice (Fig. 4c). Additional functional depletion of the interferon 
(IFN) system in mice lacking type I (Ifnar–/–), type II (Ifngr–/–) or both 
(Ifnagr–/–Rag1–/–) IFN receptors abrogated MHC class I expression after 
LCMV infection. Notably, virus replication within beta islet cells was 
detected only in mice lacking IFN type I receptors (Fig. 4c).
TLRs regulate MHC class I expression on beta cells
IFN-α is produced after ligation of TLRs with virus-related  products 
(e.g., RNA) specifically engaging TLR3 and TLR7 (refs. 24,30,31). 
We therefore analyzed the involvement of TLR stimulation in 
the  production of systemic IFN-α and upregulation of MHC 
class I on beta islet cells. Administration of the virus-related 
double-stranded RNA repeat poly(I:C)23 to naive C57BL/6 mice 
resulted in substantial production of IFN-α and upregulation of 
MHC class I expression on beta islet cells (Fig. 5a,c and Supplementary 
Fig. 1 online). This effect could be mimicked by comparable amounts 
of recombinant IFN-α (Fig. 5b). As observed for LCMV infection, 
 poly(I:C)-induced upregulation of MHC I expression on beta islet 
cells required functional IFN type I receptor signaling, as shown 
using Ifnar–/– mice (Fig. 5d). Poly(I:C)-triggered MHC I  upregulation 
was mediated by TLR3 stimulation, being absent in Tlr3–/– mice 
(Fig. 5d). Treatment of C57BL/6 mice with the low molecular weight 
immune modifier R-848 (a ligand for TLR7)32  similarly enhanced 
serum IFN-α production and pancreatic MHC class I expression 
(Fig. 5a,c and Supplementary Fig. 1 online). We found that 
IFN-α was  essential for R-848–mediated upregulation of MHC 
class I  expression, as this response was blocked by a  monoclonal 
antibody specific for IFN-α (RMMA-1, Fig. 5e). In  addition, 
mice deficient in type I IFN receptor (Ifnar–/–) were not able 
to upregulate MHC I following R-848 treatment (Fig. 5e). 
Upregulation of pancreatic MHC class I expression following 
R-848 treatment was  mediated by specific TLR signaling as shown in 
Tlr7–/– mice (Fig. 5e). R-848 induced  upregulation of MHC 
class I  expression required the presence of the common TLR 
 adaptor protein MyD88 expressed on bone marrow–derived 
cells (Fig. 5e). This strongly suggested that bone marrow derived 
cells are responsible for the observed MHC I  upregulation, 
whereas pancreatic islet cells themselves do not respond to 
R-848. Triggering of TLR4 by lipopolysaccharide, or TLR9 by CpG 
(ODN-1826) did not result in upregulated MHC class I expression on 
beta islet cells (Fig. 5c and Supplementary Fig. 1 online), consistent 
with the inability of the employed dose of CpG to enhance systemic 
IFN-α levels (Fig. 5a)33. Thus, in our  experiments, the quantities of 
IFN-α required for pancreatic islet cell MHC class I upregulation 
could only be provided through LCMV infection or by stimulation 
of TLR-3 and TLR-7.
To determine the source of IFN-α following poly(I:C) treatment, 
we analyzed sequential sections of spleens taken from mice that had 
received poly(I:C) 3 h earlier. We detected the majority of IFN-α in cell 
clusters in the marginal zone (Supplementary Fig. 2 online), consistent 
with earlier reports20,34.
TLRS convert autoreactivity into overt disease 
We showed that LCMV infection leads to the upregulation of MHC 
class I on beta islet cells and that this effect could be mimicked by 
 injection of recombinant IFN-α, the TLR3 ligand poly(I:C), or the TLR7 
Figure 2  Peptide immunization induces highly activated CTLs. (a) Expression
of CD44, CD62L, Ly6c+g and CD122 as determined by FACS. Numbers 
represent percentage of cells Ly6c+ghighCD122high (bottom) or 
CD44highCD62Llow (top). All plots representative of data obtained from four 
animals. (b) Intracellular production of IFN-γ by splenocytes after in vitro 
stimulation with or without gp33. Numbers represent percentage of CD8+ 
T cells staining positively for IFN-γ. Forty-five percent of total CD8+ T cells 
were gp33-specific; therefore nearly all tetramer-positive T cells produced 
IFN-γ. Both plots are representative of data obtained from four animals. 
(c) In vitro lytic activity as analyzed by primary and secondary 51Cr release 
assay. (d) In vivo killing activity as analyzed by an in vivo killer assay. Black 
line, splenocytes injected into gp33-immunized mice. Gray area, splenocytes 
injected into naive RIP-GP mice. Plots are representative of data obtained 
from three animals and show approximately 85% lysis of gp33-loaded cells 
in immunized recipients. (a–d) 107 splenocytes from LCMV-gp33/H-2Db-
specific TCR-transgenic 318 mice were transferred (intravenously) into naive 
RIP-GP mice later immunized with gp33 (1 mg in phosphate-buffered saline) 
on days 0, 4 and 9. Splenocytes were removed for analysis between day 11 
and 14. (e) In vivo killing activity of mice immunized with gp33 and CpG. 
FACS plots are representative of data obtained from three animals and show 
approximately 70% lysis of gp33-loaded cells in immunized recipients. 
(f) Spleen virus titers of individual C57BL/6 mice as analyzed by plaque 
assay. Mice were infected with 200 p.f.u. LCMV at day 30 or 80 after 
immunization and titers analyzed four days later. All mice in e and f were 
immunized with 1 mg gp33 together with CpG (ODN-1826, 50 µg) as 
described in Fig. 1c, or remained unmanipulated (Naive). For all panels: 
∅, without peptide. gp33, with gp33. Naive, tet-gp33- CD8+ T naive cells. 
Primed, peptide-primed tet-gp33+ CD8+ T cells.
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ligand R-848. This prompted us to investigate whether  autoimmune 
diabetes could be elicited by administration of  recombinant IFN-α or 
by ligation of TLR3 or TLR7 in RIP-GP mice that were preimmunized 
with gp33 in the absence of virus  infection. Indeed,  administration of 
IFN-α, poly(I:C) or R-848 to these  peptide- immunized mice resulted 
in a rapid and  sometimes  transient  development of  hyperglycemia 
(Fig. 5f). The ability of the TLR ligands to induce disease thus 
 correlated strictly with their  capacity to induce systemic IFN-α and 
to upregulate MHC class I on pancreatic islet cells (Fig. 5a–c and 
Supplementary Fig. 1 online). In contrast to naive mice, gp33-immu-
nized mice did not become diabetic after LCMV  infection (Fig. 
5g). This was possibly due to rapid viral clearance by primed CD8+ 
T cells and thus reduced IFN-α production in immunized mice 
(Fig. 5g). To further strengthen our hypothesis that TLR signals are 
required in addition to autoreactive T cells to induce overt  autoimmune 
disease, we investigated RIP-GP mice deficient in the common TLR 
adaptor molecule MyD88. Bone marrow chimeras were  generated 
by injection of Myd88–/– bone  marrow into lethally  irradiated 
RIP-GP or C57BL/6 mice. After LCMV immunization, C57BL/6 
bone  marrow chimeras (Myd88–/– bone marrow into C57BL/6) 
had reduced  pancreatic MHC I expression on day 8 after infection 
(Fig. 6a), and no autoimmune disease was observed in RIP-GP chimeras 
(Myd88–/– bone marrow into RIP-GP; Fig. 6b). It is noteworthy that 
in these mice, autoreactive CD8+ T cells showed a delayed expansion 
after LCMV infection (Fig. 6c), indicating a role for TLR signals in both 
innate and  adaptive immune responses. But tet-gp33+ CD8+ T cells that 
were present were functional, as assessed by intracellular IFN-γ stain-
ing and FACS  analysis (Fig. 6e) as well as in a direct ex vivo cytotoxicity 
Figure 3  Pancreatic infiltration by activated beta islet-specific CD8+ T cells is 
not sufficient to induce diabetes. 107 splenocytes from LCMV-gp33/H-2Db-
specific Vα2+ TCR-transgenic 318 mice were transferred into mice doubly 
transgenic for RIP-GP and RIP-BLC. Mice were then (a) immunized with 
gp33 (1 mg) on days 0, 4 and 9 (n = 4) or (b) infected with 200 p.f.u. LCMV 
on day 0 (n = 3). Blood glucose concentration (filled square) and percent of 
gp33-tetramer positive cells (open square) (as percentage of total CD8+ T 
cells) were monitored at the indicated time points. (c) Twenty days following 
the last peptide immunization, naive or gp33-immunized mice were killed 
and the pancreas examined for the presence of Vα2+ CD8+ T cells using 
immunohistochemistry (n = 2).
a b
c
a b c
Figure 4  LCMV infection, but not peptide immunization, results in MHC 
class I upregulation on beta islet cells. (a,b) 107 splenocytes from LCMV-
gp33/H-2Db-specific TCR-transgenic 318 mice were transferred to 
C57BL/6 mice which were then immunized with 1 mg gp33 on day 
0 and 2 or infected with 200 p.f.u. LCMV on day 0. (a) Serum IFN-α 
concentration was determined by ELISA on day 4. (n = 5–6) 
(b) Pancreatic tissue was examined by immunohistochemistry for 
MHC class I expression on day 4 and day 8 (n = 3). (c) C57BL/6, 
Rag1–/– (on C57BL/6 background) Ifnagr–/– Rag1–/– (on a mixed 
background, C57BL/6 × 129Sv), 129Sv, Ifnar–/–, and Ifngr–/– mice (on 
129Sv background) were infected with 200 p.f.u. LCMV. Eight days later, 
pancreatic tissue was stained with a general antibody specific for MHC 
class I (M1/42, staining H2-b and H2-d) and LCMV nucleoprotein as 
indicated (LCMV-NP, n = 2–3).  
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Figure 5  Toll-like receptor stimulation induces 
MHC class I upregulation on beta islet cells. 
(a) C57BL/6 mice were treated intravenously 
with recombinant IFN-α (104 units), poly(I:C) 
(200 µg), R-848 (20 µg) or CpG (ODN-1826, 
50µg) and the serum concentration of IFN-α was 
determined by ELISA 1, 6 and 24 h later 
(n = 3; only the 1 h value is shown for naive and 
IFN-α treatment). (b) C57BL/6 mice were treated 
with IFN-α (104 units) and endocrine pancreatic 
tissue analyzed for MHC class I expression 24 
h later (n = 3) with a general anti-MHC class I 
antibody (M1/42, staining H2-b and H2-d). 
(c) C57BL/6 mice were treated with poly(I:C) 
(200 µg), R-848 (20 µg), CpG (ODN-1826, 50 
µg) or lipopolysaccharide (50 µg) on day 0. At 
day 1, endocrine pancreatic tissue was analyzed 
for MHC class I expression (n = 3). Analysis for 
day 3 and 6 is shown in Supplementary Fig. 1 
online. (d) Tlr3–/– mice and control BALB/c mice 
were treated with 500 µg poly(I:C). Ifnar–/– and 
wild-type control mice (129Sv) were treated 
with 200 µg poly(I:C). Twenty-four hours later, 
the pancreas was removed and examined for 
expression of islet-cell MHC class I. (e) Tlr7–/– 
mice, Ifnar–/– mice, MyD88-deficient bone 
marrow chimeras (Myd88–/– bone marrow cells 
into C57BL/6 recipients), C57BL/6 mice treated 
with a monoclonal neutralizing antibody specific 
for IFN-α (RMMA-1, 30 µg/mouse on day 0) and 
corresponding control mice were treated with 
20 µg R-848. Twenty-four hours later pancreatic 
tissue was analyzed for MHC class I expression. 
(f,g) RIP-GP mice were immunized with gp33, 
with or without transfer of 107 splenocytes 
derived from LCMV-gp33/H-2Db-specific TCR-
transgenic 318 mice. Mice with >20% of gp33-
specific CD8+ T cells in the peripheral blood were 
further analyzed for blood glucose concentration 
(filled circle). Blood glucose concentration of 
C57BL/6 or RIP-GP mice that had not received 
gp33 immunization (open circle), or did not 
receive additional treatment (open square), 
served as controls. Mice were treated intravenously 
with 104 units IFN-α (n = 5), 200 µg of 
poly(I:C) (total n = 5) or 20 µg of R-848 (n = 4) 
at day 5 and 11 (day 3 for IFN-α) following the 
last peptide immunization. (g) At day 10–20 
after the last peptide immunization, mice were 
challenged with 200 p.f.u. of LCMV (filled 
circle). LCMV treated mice were analyzed for 
IFN-α on day 4 (n = 3). Naive RIP-GP mice 
served as controls (open circle).
f g
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assay (Fig. 6d). Chimeras lacking MyD88 (Myd88–/– bone marrow into 
C57BL/6) were able to initially suppress virus replication in a similar 
manner that observed in control chimeras (C57BL/6-negative bone 
marrow into C57BL/6). 
IFN type I is essential for virus-induced diabetes
To directly examine the requirement for type I IFNs in mediating MHC 
class I upregulation on pancreatic islet cells and the subsequent  induction 
of autoimmune disease, we crossed RIP-GP mice to Ifnar–/– mice and 
then infected these mice with LCMV. IFN type I receptor–competent 
RIP-GP mice developed diabetes with normal kinetics, whereas type I 
IFN receptor–deficient littermates remained healthy (Fig. 6g). Consistent 
with published evidence35, we observed normal CD8+ T-cell priming 
in the Ifnar–/– mice, as assessed in a direct ex vivo cytotoxicity assay 
(Fig. 6h). MHC class I expression within pancreatic islet cells was 
reduced in mice lacking type I IFN signals (Fig. 6f).
DISCUSSION
We have shown that the presence of activated and functional gp33-
specific CD8+ T cells was not sufficient for induction of  autoimmune 
disease in mice expressing LCMV-GP under 
control of the rat  insulin promoter. It has pre-
viously been shown that autoreactive CD8+ T 
cells without the chemokine CXCR3 cannot 
induce diabetes because of  inefficient homing16. 
In our experiments using double transgenic 
RIP-GP × RIP-BLC mice, we found that GP-
specific CTLs can be located within pancreatic 
endocrine tissue yet still not cause disease as 
long as the beta islet cells express only low lev-
els of MHC I. Thus, although an initial clonal 
burst of  autoreactive CD8+ T cells and their 
recruitment into the autoantigen-presenting 
peripheral organ are prerequisites for disease 
induction, other  factors exert additional  control over the onset of auto-
immune disease.
In our experiments, disease onset and  progression was further 
 determined by the ‘inflammatory status’ of the target organ, as  indicated 
by MHC class I expression by beta islet cells. This upregulation of 
MHC class I expression on beta islet cells was dependent on functional 
IFN type I receptors and seemed to be critically regulated by production 
of  systemic IFN-α. It is likely that activation of IFN type I receptors by 
IFN-β can also upregulate MHC I expression. IFN-β is also  produced 
during LCMV infection36, and it is possible that it contributes to dia-
betes in the LCMV system. This would be consistent with the finding 
that  neutralizing IFN-α antibody  treatment substantially delayed the 
onset of disease but did not prevent diabetes completely (K.L. and M.R., 
unpublished data), whereas a blockade of IFN type I receptor completely 
prevented diabetes.
Notably, cells within the pancreatic islets were more susceptible 
to upregulation of MHC class I expression than exocrine pancreatic 
 tissue,  consistent with previous observations12,14. We are currently 
 evaluating whether this mechanism holds true for other endocrine 
cells; it may  partially explain why autoimmune diseases often target 
Figure 6  Prevention of LCMV-induced diabetes 
by lack of MyD88 or IFN type I receptor. 
(a–e) Myd88–/– or Myd88+/+ bone marrow cells 
were adoptively transferred into irradiated 
C57BL/6 or RIP-GP mice. Myd88–/– > C57BL/6 
and Myd88+/+ > C57BL/6 mice were infected with 
200 p.f.u. LCMV (7 weeks later). (a) On day 8 
after infection, MHC I expression on pancreatic 
islet cells was assessed by staining with an 
general antibody specific for MHC class I (M1/42, 
staining H2-b and H2-d). CD8+ T cells of these 
mice were analyzed on the same day for direct 
ex vivo cytotoxicity (d) and for IFN-γ production 
following a 6-h peptide restimulation in vitro 
(e, n = 3). Myd88–/– > RIP-GP and Myd88+/+ > 
RIP-GP mice were infected with LCMV and blood 
sugar levels (b) and numbers of tet-gp33+ cells in 
the blood (c) were monitored (n = 4). (f–h) IFN-
α-deficient mice were crossed with RIP-GP mice. 
IFN-α-deficient mice and control littermates 
(F3 generation 129Sv × C57BL/6) were infected 
with LCMV. On day 8 after infection, splenocytes 
were analyzed for direct ex vivo cytotoxicity (h). 
In RIP-GP-negative littermates, MHC class I 
expression on pancreatic islet cells was 
assessed by immunohistology on day 8 (f). 
Ifnar–/– RIP-GP mice and Ifnar+/– RIP-GP mice 
were infected with LCMV and blood glucose was 
monitored (g, n = 4). 
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endocrine organs. There has been no previous characterization of 
the  inflammatory status of beta islet cells during health or disease; 
 however, treating  hepatitis C virus–infected human individuals with 
IFN-α  occasionally led to diabetes if beta cell–specific antibodies 
were present in the serum37. Mechanisms underlying this antibody-
mediated destruction of beta islets remain to be established.
Poly(I:C) was able to prevent diabetes in NOD (non- obese dia-
betic) mice38, but it was shown in diabetes-prone bio- breeding 
(DP-BB) rats that poly(I:C) can accelerate39,40 or prevent  diabetes, 
depending on the dosage used41. These contradictory observations 
may be partially explained by differences in doses and different kinetics 
of poly(I:C). Chronic  application of TLR ligands is known to  tolerize 
 subsequent TLR triggering42,43. In  addition, different doses of TLR 
ligands might influence the activation status of responding or anergized 
autoreactive CD8+ T cells differently.
Our manuscript shows how innate immune activation 
 influences the adaptive immune response. Blocking TLR signaling 
(e.g., Myd88–/– mice) not only abrogates innate cytokine  secretion44 
but also delays the  priming of specific T cells. Specific T cells may 
themselves augment ‘inflammatory’ signals by production of  cytokines 
(e.g., IFN-γ), which in our model may also contribute to upregulation 
of pancreatic MHC class I expression at late time points. In addition 
to TLR signaling, MyD88 is involved in signaling through the IL-1 
and IL-18 receptors45,46. Notably, IFN responses induced by virus 
infection are enhanced in the presence of IL-18 (ref. 47). We there-
fore cannot exclude a role for these cytokines in the delayed diabetes 
induction found in our Myd88–/–  experiments.
In conclusion, our experiments using the LCMV RIP-GP model 
have shown that highly activated CD8+ T cells can ‘peacefully  coexist’ 
with pancreatic beta islet cells expressing the relevant autoantigen. 
Engagement of TLRs was required to break this coexistence and 
 converted potential autoreactivity into overt autoimmune disease. 
This may indicate an important role for systemic virus infections 
in the disease-triggering phase of autoimmune diabetes in humans. 
In particular, a role for TLR signaling is consistent with the obser-
vation that overt diabetes often coincides with viral infections in 
human patients5. Alternatively, local inflammation within the pan-
creas may cause  upregulation of MHC class I and promote auto-
immunity. Taken together, our results suggest that pathogenesis of 
clinically relevant autoimmune  diseases can be viewed as a two step 
process, requiring both the  generation of autoreactive T cells and 
TLR-mediated  inflammation that renders the target organ suscep-
tible to immune attack.
METHODS
Mice and viruses. LCMV strain WE was originally obtained from F. Lehmann-
Grube (Heinrich Pette Institute) and was propagated in L929 cells. Virus titers 
were measured using a focus-forming assay as described48. Mice were infected 
with 200 p.f.u. LCMV-WE or with 2 × 106 p.f.u. recombinant vaccinia virus 
expressing the LCMV-GP (VV-G2). Mice transgenic for a T-cell receptor 
 recognizing LCMV-GP33–41 (LCMV-gp33/H-2D
b-specific TCR, 318)13, RIP-
GP mice11, RIP-GP × RIP-BLC mice28, Rag1–/– mice (Jackson Laboratory), 
Myd88–/– mice32, Tlr7–/–mice32 (N4, backcrossed on C57BL/6) and DTR mice 
(for depletion of  dendritic cells, DTR Jackson Laboratory) were maintained 
on the C57BL/6 genetic background, whereas Ifnagr–/– mice35 were of the 
129Sv genetic background. Tlr3–/– mice49 mice were on a BALB/c background. 
Ifnar–/– and Ifnar+/– mice crossed on RIP-GP mice were of mixed background 
(129Sv × C57BL/6). For generation of bone marrow chimeras, recipient mice 
were  irradiated with 950 rad on day –1. On day 0, 107 bone marrow cells were 
transferred and mice were used for experiments 7 weeks later. All mice were 
purchased from the Institute for Labortierkunde and housed under specific 
pathogen-free conditions. RIP-GP × RIP-BLC (and the corresponding RIP-GP 
mice) were used at an age of more than 10 weeks (to ensure the development of 
lymphoid structures within the pancreas of RIP-GP × RIP-BLC mice). Animal 
experiments including infection with recombinant viruses were carried out 
with authorization of the Veterinäramt of the Kanton Zurich and in accor-
dance with the Swiss law for animal protection.
Immunization with peptides or Toll-like-receptor ligands, and adoptive  transfer 
of CD8+ T cells. gp33 (KAVYNFATM) was synthesized by Neosystems. Mice 
were immunized on day 0, 2 and 5 with 1 mg gp33 and 50 µg CpG (ODN1826, 
Coley Pharmacia) and then boosted with peptide alone on day 9. For priming of 
LCMV-gp33/H-2Db-specific TCR-transgenic CD8+ T cells, 107 splenocytes were 
adoptively transferred in RIP-GP mice on day –1, and mice were immunized 
with 1 mg gp33 on day 0, day 4 and day 9. As the precursor frequency exceeded 
1% of total CD8+ T cells, no further costimulation with CpG was required 
for priming. To analyze the influence of TLRs, we treated mice with 200 µg 
poly(I:C) (Sigma-Aldrich), a ligand for TLR3; 20 µg R-848 (InvivoGen), a 
ligand for TLR7; 50 µg CpG (ODN 1826), a ligand for TLR9; or 50 µg lipo-
polysaccharide (Sigma-Aldrich) a ligand for TLR4. Recombinant mouse IFN-α 
was obtained from Hycult biotechnology (104 units/mouse). For in vivo deple-
tion of IFN-α, a rat monoclonal antibody was used (RMMA-1, Biomedical 
Laboratories, PBL).
FACS analysis. FACS analysis was performed as described previously50. Briefly, 
splenocytes or peripheral blood lymphocytes were stained using phycoerythrin-
labeled gp33 MHC class I tetramer (gp33/H-2Db) for 15 min at 37 °C, followed 
by staining with antibody specific for CD8-APC (BD PharMingen) for 30 min 
at 4 °C. For determination of their activation status, lymphocytes were stained 
with antibodies specific for CD62L, CD44, CD122 and Ly6c+g (BD PharMingen) 
for 30 min at 4 °C.
Cytotoxicity assay. 51Cr release assays were performed as previously 
described.50 EL4 target cells were loaded with 51Cr and pulsed with or 
 without gp33. Splenocytes of immunized mice were incubated directly ex 
vivo (Primary) or after restimulation with gp33 for 5 d (Secondary) with the 
target cells. Supernatant was assessed after 8 h. We performed assays for in vivo 
cytotoxicity using C57BL/6 splenocytes incubated for 1 h with or without gp33 
and labeled for 10 min with 5 µg/ml (peptide-labeled splenocytes) or 0.5µg/ml 
(peptide nonlabeled splenocytes) carboxyfluorescein diacetate  succinimidyl 
ester (CFSE, Molecular Probes), respectively. We injected 107 cells of each 
fraction  intravenously. The number of CFSE-positive cells remaining in the 
spleen after 4 h was determined by FACS analysis.
Blood glucose concentrations. Blood glucose concentrations were analyzed from 
a drop of blood using a Glucometer Elite (Bayer).
IFN-α ELISA. We performed IFN-α ELISA according to the manufacturers' 
specifications (Research Diagnostics RDI).
Histology. Histological analyses were performed on snap-frozen tissue. We stained 
sections with monoclonal antibodies against murine MHC I (M1/42)14, Vα2 
(Pharmingen), CD11b (BMA Biomedicals AG), CD11c (KB90, M0732; DAKO), 
B220 (RA3-6B2, 01121D; Pharmingen), or with VL4, a monoclonal antibody 
against the LCMV nucleoprotein48. Marginal zone was stained with MOMA-1 
(BMA Biomedicals). For staining of IFN-α, a polyclonal sheep antibody specific 
for mouse IFN-α antiserum was used (Biomedical Laboratories). Staining was 
developed using a goat anti-rat antibody (Caltag Laboratories) and an alkaline 
phosphatase-coupled donkey anti-goat antibody (Jackson ImmunoResearch) with 
naphthol AS-BI (6-bromo-2-hydroxy-3-naphtholic acid 2-methoxy anilide) phos-
phate and new fuchsin as a substrate. The presence of alkaline phosphatase activity 
yielded a red reaction product. The sections were counterstained with hemalum.
Note: Supplementary Information is available on the Nature Medicine website.
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